王建安

• 1:浙江大学医学院附属第二医院心内科经血管植入器械全国重点实验室浙江省心血管病诊治重点实验室浙江大学滨江研究院

摘要(Abstract)：

<正>瓣膜性心脏病是全球范围内心血管疾病的重要组成部分，其发病率和死亡率正随着人口老龄化的加剧而显著增加。瓣膜性心脏病已成为我国心血管疾病负担中不可忽视的因素，对患者的健康和生活质量产生了深远影响~([1])。如何优化诊断与治疗策略，改善患者预后，已成为当前医学界的重要挑战。近年来，国内外学者围绕瓣膜性心脏病的流行病学、诊断、治疗和预后管理等方面开展了大量研究，取得了显著进展。2024年我国学者通过自主创新和多学科协作，不断将国产器械、临床研究及循证证据推向国际舞台，逐步形成了具有“中国智慧”的诊疗体系。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王建安

参考文献(References)：

• [1]刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》概要(心血管疾病流行及介入诊疗状况)[J].中国介入心脏病学杂志,2024,32(10):541-550.DOI:10.3969/j.issn.1004-8812.2024.10.001.
• [2] Mack MJ,Leon MB,Thourani VH,et al.Transcatheter aortic-valve replacement with a balloon-expandable valve in lowrisk patients[J].N Engl J Med,2019,380(18):1695-1705.DOI:10.1056/NEJMoa1814052.
• [3]Popma JJ,Deeb GM,Yakubov SJ,et al.Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients[J].N Engl J Med,2019,380(18):1706-1715.DOI:10.1056/NEJMoa1816885.
• [4]Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EA CTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43(7):561-632.DOI:10.1093/eurheartj/ehab395.
• [5] Otto CM,Nishimura RA,Bonow RO,et al.2020ACC/AHA guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2021,143(5):e35-e71.DOI:10.1161/CIR.0000000000000932.
• [6]Généreux P,Schwartz A,Oldemeyer JB,et al.Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis[J].N Engl J Med,2025,392(3):217-227.DOI:10.1056/NEJMoa2405880.
• [7]Loganath K,Craig NJ,Everett RJ,et al.Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis:the EVOLVED randomized clinical trial[J].JAMA,2024:e2422730.DOI:10.1001/jama.2024.22730.
• [8]Stassen J,Ewe SH,Pio SM,et al.Managing patients with moderate aortic stenosis[J].JACC Cardiovasc Imaging,2023,16(6):837-855.DOI:10.1016/j.jcmg.2022.12.013.
• [9]Van Mieghem NM,Elmariah S,Spitzer E,et al.Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis[J].J Am Coll Cardiol,2024:S0735-1097(24)09960-1.DOI:10.1016/j.jacc.2024.10.070.
• [10]Liu X,Zhu Q,Liu Q,et al.Prognostic value of left ventricular systolic function on moderate aortic stenosis:the China-VHD study[J].Sci Bull(Beijing),2023,68(22):2717-2720.DOI:10.1016/j.scib.2023.10.023.
• [11]Windecker S,Tomii D.Transcatheter aortic valve replacement in patients with bicuspid aortic stenosis:cumulative evidence and remaining uncertainties[J].JACC Cardiovasc Interv,2024,17(14):1676-1679.DOI:10.1016/j.jcin.2024.05.028.
• [12]Williams MR,Jilaihawi H,Makkar R,et al.The PARTNER3 bicuspid registry for transcatheter aortic valve replacement in low-surgical-risk patients[J].JACC Cardiovasc Interv,2022,15(5):523-532.DOI:10.1016/j.jcin.2022.01.279.
• [13] Forrest JK,Ramlawi B,Deeb GM,et al.Transcatheter aortic valve replacement in low-risk patients with bicuspid aorticvalve stenosis[J].JAMA Cardiol,2021,6(1):50-57.DOI:10.1001/j amacardio.2020.4738.
• [14]Waksman R,Craig PE,Torguson R,et al.Transcatheter aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic valve stenosis[J].JACC Cardiovasc Interv,2020,13(9):1019-1027.DOI:10.1016/j.jcin.2020.02.008.
• [15]Jorgensen TH,Thyregod H,Savontaus M,et al.Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis:the NOTION-2 trial[J].Eur Heart J,2024,45(37):3804-3814.DOI:10.1093/eurheartj/ehae331.
• [16]Guo Y,Liu X,Li R,et al.Comparison of downsizing strategy(HANGZHOU Solution)and standard annulus sizing strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement:rationale and design of a randomized clinical trial[J].Am Heart J,2024,274:65-74.DOI:10.1016/j.ahj.2024.04.011.
• [17]Li HD,Li WY,Li JL,et al.Long-term durability of transcatheter aortic valve prostheses in patients with bicuspid versus tricuspid aortie valve[J].J Am Heart Assoc,2024.13(21):e035772.DOI:10.1111/JAHA.124.035772.
• [18]Vahl TP,Thourani VH,Makkar RR,et al.Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation(ALIGN-AR):a prospective,multicentre,single-arm study[J].Lancet,2024,403(10435):1451-1459.DOI:10.1016/S0140-6736(23)02806-4.
• [19]Zhang J,Kong XQ,Gao XF,et al.Transfemoral transcatheter aortic valve replacement with VitaFlow~(TM)valve for pure native aortic regurgitation in patients with high surgical risk:rationale and design of a prospective,multicenter,and randomized SEASON-AR trial[J].Am Heart J,2024,271:76-83.DOI:10.1016/j.ahj.2024.02.022.
• [20]Anker SD,Friede T,von Bardeleben RS,et al.Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation[J].N Engl J Med,2024,391(19):1799-1809.DOI:10.1056/NEJMoa2314328.
• [21]Baldus S,Doenst T,Pfister R,et al.Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation[J].N Engl J Med,2024,391(19):1787-1798.DOI:10.1056/NEJMoa2408739.
• [22]Wang J,Liu X,Pu Z,et al.Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation:one-year results of the DRAGONFLY-DMR trial[J].Euro Intervention,2024,20(4):e239-e249.DOI:10.4244/EIJ-D-23-00361.
• [23]Hahn RT,Makkar R,Thourani VH,et al.Transcatheter valve replacement in severe tricuspid regurgitation[J].N Engl J Med,2025,392(2):115-126.DOI:10.1056/NEJMoa2401918.
• [24]Stolz L,Cheung A,Boone R,et al.Transjugular transcatheter tricuspid valve replacement:early compassionate use outcomes[J].JACC Cardiovasc Interv,2024,17(16):1936-1945.DOI:10.1016/j.jcin.2024.06.014.
• [25] Xu H,Chen M,Wang Z,et al.Mid-term outcomes of K-Clip transcatheter tricuspid annuloplasty system in patients with severe functional tricuspid regurgitation[J].JACC Cardiovasc Interv,2024,17(23):2796-2807.DOI:10.1016/j.jcin.2024.10.007.
• [26]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经导管三尖瓣反流介入治疗的专家建议[J].中华心血管病杂志,2024,52(10):1138-1147.DOI:10.3760/cma.j.cn112148-20231012-00310.